Overview

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Status:
Completed
Trial end date:
2008-08-22
Target enrollment:
Participant gender:
Summary
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will evaluate the safety, tolerability and pharmacokinetics of repeat doses of GSK598809 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Caffeine